Company Description
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases.
The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.
It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.
In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials.
Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr.
Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program.
The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016.
The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
| Country | United States |
| Founded | 1992 |
| IPO Date | Aug 8, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Jed Latkin |
Contact Details
Address: 2600 Kelly Road, Suite 100 Warrington, Pennsylvania 18976-3622 United States | |
| Phone | 215 488 9300 |
| Website | windtreetx.com |
Stock Details
| Ticker Symbol | WINT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000946486 |
| CUSIP Number | 97382D303 |
| ISIN Number | US97382D4025 |
| Employer ID | 94-3171943 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig E. Fraser | President, Chief Executive Officer and Chairman |
| Eric L. Curtis M.B.A. | Senior Vice President and Chief Operating Officer |
| Dr. Steven G. Simonson M.D., M.H.S | Senior Vice President and Chief Medical Officer |
| Jamie McAndrew | Senior Vice President, Chief Financial Officer, Chief Accounting Officer, Controller and Corporate Secretary |
| George Cox | Vice President of Technical Operations |
| Dr. Pratap Paruchuru | Executive Director of Clinical Development |
| Tracy Rarick | Head of Operations and Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2024 | PRE 14A | Other preliminary proxy statements |
| Dec 5, 2024 | 8-K | Current Report |
| Dec 4, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 10-Q | Quarterly Report |
| Nov 15, 2024 | 8-K/A | [Amend] Current report |
| Nov 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |